USADA announced today that Micael Galvão, of São Paulo, Brazil, an athlete in the sport of Brazilian Jiu-Jitsu, has accepted a one-year suspension for an anti-doping rule violation.
Galvão, 19, tested positive for clomiphene and its metabolite 4-hydroxyclomiphene as the result of an in-competition drug test conducted at the International Brazilian Jiu-Jitsu Federation (IBJJF) World Jiu-Jitsu Championships on June 5, 2022. Although the IBJJF is not a signatory to the World Anti-Doping Code (the Code), USADA was contracted by IBJJF to conduct testing for the event and collected and analyzed Galvão’s sample in accordance with the World Anti-Doping Agency’s International Standards.
Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the Code and the USADA Protocol for Olympic and Paralympic Movement Testing, which applied with slight modifications, to the 2022 IBJJF World Jiu-Jitsu Championships.
After a thorough review of the case, including the examination of medical records provided by the athlete, USADA determined that Galvão’s positive test was caused by a medication prescribed in a therapeutic dose under the care of a physician. Although the substance was taken at the direction of a physician, the Code requires that athletes obtain a TUE before using a prohibited substance, which Galvão failed to do.
Galvão’s one-year period of ineligibility began on July 22, 2022, the date his provisional suspension was imposed. In addition, Galvão has been disqualified from all competitive results achieved in competitions sanctioned by the IBJJF, or any Code signatory, on and subsequent to June 5, 2022, the date his positive sample was collected, including forfeiture of any medals, points, and prizes. IBJJF has agreed to impose the sanction.
In an effort to aid athletes, as well as support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to file and update athlete Whereabouts, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements, as well as performance-enhancing and recreational drugs.
In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and distributes a multitude of educational materials, such as a supplement guide, a nutrition guide, a clean sport handbook, and periodic alerts and advisories.
USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by text at 87232 (“USADA”), by email at playclean@USADA.org, by phone at 1-877-Play Clean (1-877-752-9253) or by mail.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
For more information or media inquiries, click here.